PHARMACOSMOS ASSUMES GLOBAL RIGHTS TO LEROCICLIB OUTSIDE ASIA-PACIFIC

Press Release – Holbæk, May 12th 2025

Pharmacosmos assumes global rights to lerociclib outside Asia-Pacific

Pharmacosmos A/S today announced that it has assumed the worldwide rights, excluding select Asia-Pacific territories, to the investigational oncology asset lerociclib. These rights were previously out-licensed by G1 Therapeutics, Inc., the original developer of lerociclib, to Pepper Bio and Deimos Biosciences. Following Pharmacosmos’ acquisition of G1 Therapeutics in September 2024, both license agreements have been concluded and the rights have transitioned back to Pharmacosmos.

Lerociclib is an investigational oral, selective CDK4/6 inhibitor that is designed to disrupt cancer cell proliferation by blocking cell cycle progression from the G1 to S phase. The compound holds the potential to be developed as a treatment for a number of solid tumors including hormone receptor-positive/HER2-negative (HR+/HER2−) advanced or metastatic breast cancer and hepatocellular carcinoma (HCC), the most common form of liver cancer. Lerociclib is currently under regulatory review in China for the treatment of HR+/HER2− advanced breast cancer, based on positive Phase 3 clinical data.

With full rights now consolidated, Pharmacosmos holds exclusive development and commercialization rights to lerociclib in all countries except Australia, Bangladesh, Mainland China, Hong Kong SAR, India, Indonesia, Macau SAR, Malaysia, Myanmar, New Zealand, Pakistan, the Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, and Vietnam.

“Securing the global rights to lerociclib outside Asia-Pacific enables us to explore the potential of a promising oncology asset with multiple development opportunities,” said Claes C Strom, Chief Commercial Officer, Pharmacosmos A/S. “We are now evaluating the best path forward to bring lerociclib to patients, including through new strategic partnerships.”

About Pharmacosmos

Pharmacosmos A/S is a global leader in carbohydrate chemistry and innovative treatments for iron deficiency and iron deficiency anaemia. Building on our foundational expertise in carbohydrate chemistry and cell cycle biology, we develop innovative treatments for unmet patient needs, with a focus on iron metabolism and blood-related disorders. Founded in 1965 and headquartered in Denmark, our team is made up of more than 700 specialists across the UK, Ireland, the Nordics, Germany, the USA, and China

For more information, please contact:

Christian Lundquist Madsen

VP, Corporate Communication

Pharmacosmos

Phone: +45 5948 5959

Email: clm@pharmacosmos.com